CA2355348A1 - Methode pour traiter le lupus erythemateux systemique chez les individus qui ont une grave deficience renale - Google Patents

Methode pour traiter le lupus erythemateux systemique chez les individus qui ont une grave deficience renale Download PDF

Info

Publication number
CA2355348A1
CA2355348A1 CA002355348A CA2355348A CA2355348A1 CA 2355348 A1 CA2355348 A1 CA 2355348A1 CA 002355348 A CA002355348 A CA 002355348A CA 2355348 A CA2355348 A CA 2355348A CA 2355348 A1 CA2355348 A1 CA 2355348A1
Authority
CA
Canada
Prior art keywords
individual
conjugate
affinity
dsdna
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002355348A
Other languages
English (en)
Inventor
Matthew D. Linnik
Bonnie Hepburn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
La Jolla Pharmaceutical Co
Original Assignee
La Jolla Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by La Jolla Pharmaceutical Co filed Critical La Jolla Pharmaceutical Co
Priority to CA002355348A priority Critical patent/CA2355348A1/fr
Publication of CA2355348A1 publication Critical patent/CA2355348A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002355348A 2001-08-23 2001-08-23 Methode pour traiter le lupus erythemateux systemique chez les individus qui ont une grave deficience renale Abandoned CA2355348A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002355348A CA2355348A1 (fr) 2001-08-23 2001-08-23 Methode pour traiter le lupus erythemateux systemique chez les individus qui ont une grave deficience renale

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002355348A CA2355348A1 (fr) 2001-08-23 2001-08-23 Methode pour traiter le lupus erythemateux systemique chez les individus qui ont une grave deficience renale

Publications (1)

Publication Number Publication Date
CA2355348A1 true CA2355348A1 (fr) 2003-02-23

Family

ID=4169748

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002355348A Abandoned CA2355348A1 (fr) 2001-08-23 2001-08-23 Methode pour traiter le lupus erythemateux systemique chez les individus qui ont une grave deficience renale

Country Status (1)

Country Link
CA (1) CA2355348A1 (fr)

Similar Documents

Publication Publication Date Title
US20070191297A1 (en) Methods of treating and monitoring systemic lupus erythematosus in individuals
AU2021201773B2 (en) Methods and compositions for treating autoimmune and inflammatory conditions
US20060142229A1 (en) Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof
US20100152281A1 (en) Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function
US10570208B2 (en) Antagonistic anti-OX40L antibodies and methods of their use
JP6190276B2 (ja) 自己免疫疾患の治療及び／又は診断におけるアプタマーの使用
US20070218072A1 (en) Methods of improving health-related quality of life in individuals with systemic lupus erythematosus
JP2002531531A (ja) 循環している抗体を減少させるための方法および処方物
US20070179111A1 (en) Methods of treating proteinuria by reducing double-stranded dna antibodies
CA2355348A1 (fr) Methode pour traiter le lupus erythemateux systemique chez les individus qui ont une grave deficience renale
US20240226292A1 (en) Methods and compositions for targeting of antigens and other polypeptides to first responder dendritic cells

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead